Pharmacokinetic profiles of the active metamizole metabolites in healthy horses.

The research article discusses a study conducted to investigate the pharmacokinetic profiles of the active metabolites of metamizole, a pain reliever and fever reducer, in healthy horses. The study focussed particularly on metamizole’s active primary metabolite 4-methylaminoantipyrine (MAA) and another active secondary metabolite 4-aminoantipyrine (AA) and their concentration levels in horse plasma post administration of the drug via intravenous and intramuscular routes.

Objective of the Study

• The purpose of this research was to assess the pharmacokinetic behavior of MAA and AA active metabolites of metamizole in healthy horses after delivery of a 25mg/kg MT dose through intravenous (i.v.) and intramuscular (i.m.) routes. This study utilized a 2×2 crossover study design where horses were randomly categorized into two equal-sized treatment groups.
• Metamizole is a drug used for pain management and reduction of fever, approved for use in various animals including horses, cattle, and dogs. Despite its widespread use, little research had been conducted on how its active metabolites, MAA and AA, behaved within the body of horses after administration.

Methodology and Results

• During the experiment, blood samples were taken from the horses at pre-specified points within a 24 hour period following drug administration. The plasma was then analyzed using a validated High-Performance Liquid Chromatography-Ultraviolet (HPLC-UV) method.
• The study observed no behavioral changes or alterations in health parameters in either of the treatment groups, for a period up to 7 days post drug administration.
• MAA’s presence in the plasma following both i.v and i.m administrations of MT was observable from 5 minutes up to 10 hours in all horses. AA was detected over the same period but in relatively less quantity.
• Statistical differences were noted in maximum concentration (C), time to maximum concentration (T), and AUMC (area under the first moment curve, a measure of drug exposure) of MAA between the two groups. The AUC (area under the curve, a pharmacokinetic measure of total drug exposure) of AA was statistically different between the groups.

Conclusion

• The findings of this study suggest that the difference in MAA and AA plasma concentrations noted after i.m. and i.v. administration of MT may have a marginal impact on the pharmacodynamics of the drug. This implies that while the levels of these active metabolites varied slightly depending on the method of delivery, it contained minor consequences on how the drug behaved pharmacologically within the horse’s body.